Update
$Journey Medical (DERM.US)$ Journey Medical Presents DFD-29 Data At 44th Fall Clinical Dermatology Conference
Benzinga· 3 mins ago
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea) in Healthy Subjects
With its modified-release formulation, DFD-29 (40 mg) provides higher dermal concentration than doxycycline from Day 1 onward at a similar dose, expected to translate into a clinically meaningful impact for treating patients with rosacea
New Drug Application for DFD-29 under review by FDA with PDUFA goal date of November 4, 2024
Benzinga· 3 mins ago
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea) in Healthy Subjects
With its modified-release formulation, DFD-29 (40 mg) provides higher dermal concentration than doxycycline from Day 1 onward at a similar dose, expected to translate into a clinically meaningful impact for treating patients with rosacea
New Drug Application for DFD-29 under review by FDA with PDUFA goal date of November 4, 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
HannChau : PDUFA date on Nov 4 right ?
Trytosaveabit OP HannChau : Yes it’s on PDUFA calendar for November 4